{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["107(45)"],"submitter":["Donnelly J"],"pubmed_abstract":["A unique multicomponent vaccine against serogroup B meningococci incorporates the novel genome-derived proteins fHbp, NHBA, and NadA that may vary in sequence and level of expression. Measuring the effectiveness of such vaccines, using the accepted correlate of protection against invasive meningococcal disease, could require performing the serum bactericidal assay (SBA) against many diverse strains for each geographic region. This approach is impractical, especially for infants, where serum volumes are very limited. To address this, we developed the meningococcal antigen typing system (MATS) by combining a unique vaccine antigen-specific ELISA, which detects qualitative and quantitative differences in antigens, with PorA genotyping information. The ELISA correlates with killing of strains "],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pagination":["19490-5"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2984153"],"repository":["biostudies-literature"],"pubmed_title":["Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines."],"pmcid":["PMC2984153"],"pubmed_authors":["Santini L","Biolchi A","Boccadifuoco G","Comanducci M","Chen J","Ward J","Frasch C","Bambini S","Giuliani MM","Donnelly J","Medini D","Boucher P","Muzzi A","Santos G","Stella M","Moxon ER","Pizza M","Andrews W","Serruto D","Rappuoli R"],"additional_accession":[]},"is_claimable":false,"name":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.","description":"A unique multicomponent vaccine against serogroup B meningococci incorporates the novel genome-derived proteins fHbp, NHBA, and NadA that may vary in sequence and level of expression. Measuring the effectiveness of such vaccines, using the accepted correlate of protection against invasive meningococcal disease, could require performing the serum bactericidal assay (SBA) against many diverse strains for each geographic region. This approach is impractical, especially for infants, where serum volumes are very limited. To address this, we developed the meningococcal antigen typing system (MATS) by combining a unique vaccine antigen-specific ELISA, which detects qualitative and quantitative differences in antigens, with PorA genotyping information. The ELISA correlates with killing of strains ","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Nov","modification":"2025-04-21T16:05:09.36Z","creation":"2019-03-27T00:36:40Z"},"accession":"S-EPMC2984153","cross_references":{"pubmed":["20962280"],"doi":["10.1073/pnas.1013758107"]}}